Introduction
============

Oral squamous cell carcinoma (OSCC) accounts for \>90% of primary oral malignancies worldwide ([@b1-ol-0-0-10415]). A combination of different genetic features and environmental factors contributes to the oncogenesis of OSCC ([@b2-ol-0-0-10415]). Although treatment methods, including chemotherapy, radiotherapy and surgery, have advanced, the 5-year overall survival rate of patients with OSCC remains \~50% ([@b3-ol-0-0-10415]). Locoregional recurrence, metastatic disease and second primary tumors are the main factors contributing to the poor survival rate of patients with OSCC ([@b4-ol-0-0-10415]).

OSCCs are often ulcerated with a large number of lymphocyte infiltration. An improved understanding of the tumor immune microenvironment, including number, location and function of infiltrating lymphocytes is crucial in order to examine and test immunotherapeutic strategies, which may prolong the survival time of patients with OSCC ([@b5-ol-0-0-10415]). Tumor-infiltrating lymphocytes (TILs) are considered to be the host immune response to tumor cells ([@b6-ol-0-0-10415]). To date, a number of studies have reported an association between the TILs subset and patient prognosis in various types of cancer ([@b6-ol-0-0-10415],[@b7-ol-0-0-10415]). Tumor infiltration by CD8^+^ T cells, including cytotoxic T cells (CTLs), has been indicated to be associated with an improved prognosis in various types of malignant tumors ([@b7-ol-0-0-10415]). In turn, increasing evidence has demonstrated that tumor-infiltrating forkhead box P3 (FoxP3)^+^ immunosuppressive regulatory T cells (Tregs) are associated with poor prognosis, and suppressed function on host antitumor immunity ([@b8-ol-0-0-10415]). The ratio of cytotoxic CD8^+^ T cells and FoxP3^+^ Tregs in the tumor microenvironment has been indicated to be a prognostic factor in in various types of cancer ([@b9-ol-0-0-10415]--[@b11-ol-0-0-10415]). However, further investigations on the role of TILs in OSCC are required.

C-X-C motif chemokine ligand 12 (CXCL12) serves multiple tumor promoting functions via its cognate receptor C-X-C motif chemokine receptor (CXCR)4 present in cancer cells; either directly, by enhancing tumor growth, migration and invasiveness, or indirectly, by recruiting endothelial progenitors required for tumor angiogenesis ([@b12-ol-0-0-10415],[@b13-ol-0-0-10415]). In addition, CXCL12 promotes tumor immunosuppression by recruiting specific immune cell populations ([@b13-ol-0-0-10415]). Therefore, it may be hypothesized that the expression levels of CXCL12 in OSCC are associated with tumor progression and immune suppression. To examine this hypothesis, the present study investigated the association among clinicopathological parameters of OSCC and CXCL12, densities of CD8^+^ T cells and FoxP3^+^ T cells. In addition, the present study examined whether CXCL12 expression can influence CD8^+^ T cells or FoxP3^+^ T cells distribution in patients with OSCC.

Patients and methods
====================

### Patients and sample collection

The present study was performed on a retrospective cohort of 45 Chinese patients with primary OSCC. A total of 24 patients were male and 21 were female, and the median age was 61 (range, 37--81 years). Paraffin-embedded tissue specimens, including OSCC tissue and adjacent non-cancerous tissue, were collected from the West China College of Stomatology, Sichuan University between January 2011 and December 2011. All patients underwent radical surgery with neck dissection without receiving any preoperative radiotherapy and chemotherapy. All patients signed informed consent forms prior to the present study. Data from patient follow-up and clinicopathological characteristics were collected from the database of West China College of Stomatology and telephone interviews. Clinical staging was established according to the American Joint Committee on Cancer Staging Manual (2009) ([@b14-ol-0-0-10415]). The present study was approved by the Institutional Review Board of West China Hospital of Stomatology of Sichuan University.

### Immunohistochemistry

Formalin-fixed at 4°C for 24 h, paraffin-embedded tissues, obtained from the Department of Pathology, West China Hospital of Stomatology, were consecutively cut into 5-µm sections and transferred onto silanized glass slides. Immunohistochemistry for CXCL12, CD8 and FoxP3 was performed using standard procedures ([@b8-ol-0-0-10415],[@b9-ol-0-0-10415]). Briefly, 5-µm tissue sections were dewaxed and rehydrated using xylene and graded alcohol washes. The slides were heated to 121°C for 2 min for antigen retrieval in citrate buffer (pH 6.0). Following serial blocking with 3% hydrogen peroxide and 5% normal goat serum (cat. no., ZLI-9022; OriGene Technologies, Inc.) at 37°C for 20 min, the sections were incubated with primary monoclonal antibody against CD8 (dilution, 1:100; clone C8/144B; Dako), CXCL12 (dilution, 1:400; cat. no. ab9797; Abcam) or FoxP3 (dilution 1:100; cat. no. ab20034; Abcam) for 16 h at 4°C. The sections were then incubated with biotinylated goat anti-mouse immunoglobulin and peroxidase-conjugated streptavidin (dilution, 1:100; cat. no., cat. no., ab64255; Abcam) at 37°C for 30 min. The enzyme substrate was 3,3′-diaminobenzidine tetrahydrochloride. Tissue section were analyzed using a light microscope. Negative controls were performed with PBS instead of the primary antibody.

### Evaluation of immunohistochemistry results

For CXCL12 expression, the respective score was calculated according to a visual grading scale based on the percentage of positive cells and the intensity of staining. The percentage scale was as follows: 0, \<5; 1, 5--25; 2, 25--50; 3, 50--75; and 4, \>75%. The intensity scale was as follows: 0, none; 1, weak staining; 2, moderate staining; and 3, strong staining. Five representative fields of view were evaluated (magnification, ×400). The final weighted score was calculated for each case by multiplying the two scores: \<1, negative; ≥1, positive ([@b15-ol-0-0-10415]). The patients were divided into high and low expression CXCL12 groups according to the median values.

For CD8^+^ T and FoxP3^+^ T cells, tissue sections were examined microscopically (magnification, ×400), five high-power fields of each case with the most abundant TILs were selected for image capturing at an area of 0.0625 mm^2^, and the numbers of CD8^+^ T and FoxP3^+^ T cells in each field were counted in the same five areas of serial sections. The mean value represented the number of lymphocyte infiltration, as described previously ([@b16-ol-0-0-10415]).

### Statistical analysis

The data was presented as mean ± standard deviation. For CXCL12 expression and TILs densities, five areas were measured and the mean score of the five areas was collected for further analyses. Associations among clinicopathological features, CXCL12 expression and densities of TILs were evaluated using the χ^2^ test. The variables were dichotomized via median splits. Survival curves were plotted using the Kaplan-Meier method, and significant differences in the overall survival rate were assessed using a log-rank test. The correlation between variables was calculated by linear regression. P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS version 19.0 (IBM Corp.).

Results
=======

### Characteristics of patients with OSCC included in the present study

Between January 2011 and December 2011, a total of 45 specimens were collected from 45 pathologically confirmed patients with OSCC. Out of these patients, 24 were male, 29 had advanced disease, 14 exhibited poor differentiation and 19 exhibited positive lymph node metastasis.

### General features of TILs in OSCC

TILs were distributed in the cancer cell nests and in the stroma of the tumor-host interface. The majority of FoxP3^+^ T cells were located in the stroma ([Fig. 1B](#f1-ol-0-0-10415){ref-type="fig"}). However, CD8^+^ T cells infiltrated not only the stroma of the tumor-host interface but also the cancer cell nests ([Fig. 1A](#f1-ol-0-0-10415){ref-type="fig"}). CD8^+^ TILs and FoxP3^+^ TILs were present in every case, with an average number of 111.9 and 50.4 per 0.0625 mm^2^, respectively ([Table I](#tI-ol-0-0-10415){ref-type="table"}). The median value of the CD8^+^/FoxP3^+^ ratio was 2.07, ranging between 0.1 and 20 (data not shown).

### Expression levels of CXCL12 in OSCC cells

Among the available specimens, 11 specimens included OSCC tissues and adjacent non-cancerous tissues (epithelia and stroma). The non-cancerous tissues were collected from 0.5--1 cm apart from the margin. These samples were selected to compare CXCL12 expression between tumor adjacent tissues and OSCC tissues. The present study demonstrated that, in these specimens, CXCL12 could not be detected in adjacent non-cancerous tissues ([Fig. 2A](#f2-ol-0-0-10415){ref-type="fig"}). CXCL12 expression in OSCC cells was observed in 68.9% (31/45) of OSCC cases. Cytoplasmic and intracellular staining patterns were observed in OSCC tissues ([Fig. 2B](#f2-ol-0-0-10415){ref-type="fig"}).

### Association among TILs density in the tumor microenvironment and clinicopathological features/survival of patients with OSCC

Associations among clinicopathological features and TILs density are summarized in [Table II](#tII-ol-0-0-10415){ref-type="table"}. An increased number of FoxP3^+^ TILs was associated with tumor recurrence (P=0.022) in patients with OSCC. There was no significant association identified among the density of CD8^+^ TILs and any of the clinicopathological features of patients with OSCC examined in the present study. Furthermore, neither the density of CD8^+^ TILs nor the density of FoxP3^+^ TILs were associated with patient survival ([Fig. 3A and B](#f3-ol-0-0-10415){ref-type="fig"}). However, the ratio of these two types of TILs was suggested to be more important compared with their densities when evaluating the clinicopathological features and survival of patients ([@b9-ol-0-0-10415]). In particular, a low CD8^+^/FoxP3^+^ ratio was significantly associated with poor differentiation (P=0.034), advanced stage tumors (P=0.015) and tumor recurrence (P=0.002). In addition, low CD8^+^/FoxP3^+^ TILs ratios were associated with a poor 5-year overall survival rate (P\<0.001; [Fig. 3C](#f3-ol-0-0-10415){ref-type="fig"}).

### Association between CXCL12 expression and clinicopathological features/survival of patients with OSCC

As indicated in [Table III](#tIII-ol-0-0-10415){ref-type="table"}, patients with poor differentiation (P=0.045), advanced stage tumors (P\<0.001) and tumor recurrence (P=0.011) tended to exhibit a higher CXCL12 expression level. No significant associations among CXCL12 expression and lymph node metastasis (P=0.200) and tumor size (P=0.200) were identified. In addition, high CXCL12 expression was associated with poor overall survival (P=0.0476; [Fig. 3D](#f3-ol-0-0-10415){ref-type="fig"}).

### Association between CXCL12 expression and TILs density

The density of FoxP3^+^ TILs exhibited a significant positive association with the CXCL12 expression of tumor cells (P\<0.001). However, the density of CD8^+^ TILs was not identified to be associated with CXCL12 expression (P=0.095). In addition, the ratio of CD8^+^/FoxP3^+^ exhibited a significant negative association with CXCL12 expression (P\<0.001; [Table III](#tIII-ol-0-0-10415){ref-type="table"}).

To investigate the association between TILs and CXCL12 expression, a linear regression test was performed. The results indicated a correlation between CXCL12 percentage area and the density of FoxP3^+^ TILs (R^2^=0.481, P\<0.001; [Fig. 4A](#f4-ol-0-0-10415){ref-type="fig"}). By contrast, the CD8^+^ TILs were not identified to be significantly correlated with CXCL12 percentage area (R^2^=0.070, P=0.078; [Fig. 4B](#f4-ol-0-0-10415){ref-type="fig"}). Further observations revealed that the higher the expression level of CXCL12, the larger the number of FoxP3^+^ T-cells infiltrating in the tumor microenvironment ([Fig. 5A and B](#f5-ol-0-0-10415){ref-type="fig"}). Conversely, FoxP3^+^ T-cells hardly infiltrated in the region with low CXCL12 expression ([Fig. 5A and B](#f5-ol-0-0-10415){ref-type="fig"}).

Discussion
==========

CXCL12 was initially known as a chemotactic factor for T cells and monocytes, and as a growth factor for B cell progenitor cells. In recent years, there has been an increasing number of studies focusing on the pathological characteristics of CXCL12 in the tumor microenvironment ([@b12-ol-0-0-10415],[@b13-ol-0-0-10415]). Particularly, attention has been drawn to the tumor microenvironment suppressing the effectiveness of immune responses by trafficking and retaining these immunosuppressive cells ([@b17-ol-0-0-10415]). However, further studies are required regarding the role of CXCL12 in OSCC. In the present study, the expression levels of CXCL12 were investigated as a novel prognostic factors in the treatment of OSCC. High expression levels of CXCL12 may contribute to a high recurrence rate and a low 5-year overall survival rate. The results of a previous study are in accordance with the results of the present study. In particular, Clatot *et al* ([@b18-ol-0-0-10415]) investigated 71 patients with primary head and neck squamous cell carcinoma, and revealed that CXCL12 expression is significantly associated with metastatic evolution and overall survival.

TILs in the tumor microenvironment may reflect tumor biology and predict prognosis. However, further examination is required to investigate whether lymphocyte infiltration at the primary tumor site represents a beneficial antitumor immune response in the tumor microenvironment, or whether it is implicated as a poor prognostic factor, promoting tumor progression by releasing regulatory cytokines ([@b19-ol-0-0-10415],[@b20-ol-0-0-10415]). CTLs belong to the CD8 population, a major subpopulation which has been suggested to aid in the promotion of immune mediated tumor regression and serve as a response indicator in chemotherapy in a number of types of cancer ([@b7-ol-0-0-10415],[@b9-ol-0-0-10415]). A number of studies have indicated that decreased numbers of nest and stromal CD8^+^ T cells were associated with lower survival time in patients with OSCC ([@b5-ol-0-0-10415],[@b21-ol-0-0-10415]). The present study reported that the density of CD8^+^ TILs was not associated with the overall survival or any of the clinicopathological features of OSCC. Therefore, taking the aforementioned into consideration, it is controversial to regard CD8^+^ TILs as an independent prognostic factor.

The development and function of Tregs depends on the expression of FoxP3, which has been reported as the master regulator ([@b22-ol-0-0-10415]). Tumor cells have the ability to recruit Tregs to the tumor microenvironment to inhibit antitumor immunity in patients with cancer. It has been reported that a population of FoxP3^+^ regulatory T cells serves as a predicting factor for survival in colon cancer ([@b22-ol-0-0-10415]). In the present study, FoxP3^+^ TILs were significantly associated with tumor recurrence. Furthermore, it was indicated that a high density of FoxP3^+^ TILs in OSCC tissue is associated with poor survival, however this result was not significant (P=0.083). The number of FoxP3^+^ TILs tended to be sparse in early stage OSCC and in well-differentiated OSCC. Conversely, in the present study, expression levels of FoxP3^+^ TILs were higher in advanced stage OSCC and poorly-differentiated OSCC. This finding may indicate that FoxP3^+^ TILs may serve an important role in suppressing an antitumor immune response in advanced OSCC compared to early OSCC. However, another study revealed that higher peripheral blood levels of this subset were associated with improved survival in patients with oropharyngeal cancer ([@b5-ol-0-0-10415]). Another study on tumor infiltration suggested that high expression levels of FoxP3 infiltration are associated with an increased survival rate in patients with head and neck cancer ([@b23-ol-0-0-10415]).

Therefore, the balance between the CD8^+^ TILs and FoxP3^+^ TILs is significant. In the present study, the CD8^+^/FoxP3^+^ ratio was revealed to be the strongest prognostic indicator and was associated with poor differentiation, advanced stage tumors, tumor recurrence and poor survival rates. A previous study demonstrated that the CD8^+^/C-C motif chemokine receptor 4^+^ T-cells ratio was the most significant prognostic factor among all TIL-associated variables ([@b6-ol-0-0-10415]). Additionally, various types of immune cells can be attracted to the tumor environment via CXCL12 ([@b24-ol-0-0-10415],[@b25-ol-0-0-10415]).

Thus, the present study investigated the associations among CXCL12 expression and FoxP3^+^ TILs and CD8^+^ TILs in OSCC. Notably, the present study revealed that FoxP3^+^ TIL counts and CXCL12 percentage area exhibited a significant correlation. However, no significant correlation was detected for CD8^+^ TILs and CXCL12 percentage area. In addition, the present study identified that some stroma cells with high CXCL12 expression were surrounded by numerous FoxP3^+^ TILs, which may support the result of a correlation between FoxP3^+^ TIL counts and CXCL12 percentage area. Therefore, the present study demonstrated that CXCL12 may contribute to tumor immunosuppression by recruiting FoxP3^+^ T-cell populations in OSCC. The chemokine CXCL12 is a well-known T-cell chemoattractant that selectively binds its receptors CXCR4 and CXCR7. Activation of Tregs upregulates CXCR4 or CXCR7 expression and drives them to migrate to the tumor microenvironment in a CXCL12-dependent manner ([@b24-ol-0-0-10415]). A recent study indicated that inhibition of CXCL12 expression may increase the number of tumor-infiltrating lymphocytes and overcome resistance to anti-programmed cell death protein 1 treatment ([@b26-ol-0-0-10415]). Additionally, CXCL12 and CXCR4 may attract the myeloid-derived suppressor cells into the tumor microenvironment in ovarian cancer ([@b25-ol-0-0-10415]).

In conclusion, the present study indicated that some clinicopathological parameters, including tumor differentiation, tumor stage and overall survival, were significantly associated with the CD8^+^/FoxP3^+^ ratio and CXCL12 expression. Overall, these findings supported the hypothesis that high expression levels of CXCL12 may lead to FoxP3^+^ T-cells accumulation in the progression of OSCC. However, the underlying mechanism of CXCL12 in recruiting FoxP3^+^ TILs in OSCC remains unclear. In addition, considering the limited sample size, the subgroup survival analysis of CXCL12 could not be conducted. Therefore, further large and long-term studies are required to validate and supplement the findings of the present study. The present study indicated that CXCL12 is a potential prognostic marker that may assist in the pathological analysis of OSCC. Recently, immunotherapy has become an increasingly important treatment strategy in tumor therapy. Specific blocking of CXCL12 is expected to enhance the effects of immunotherapy for OSCC in the future.
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![Representative images of tumor-infiltrating lymphocytes in oral squamous cell carcinoma. (A) CD8^+^ T cells which infiltrated the cancer nest and stroma. (B) Forkhead box P3^+^ T cells. Infiltration was mostly confined to the cancer stroma.](ol-18-02-1099-g00){#f1-ol-0-0-10415}

![Representative images of immunohistochemical CXCL12 staining. (A) CXCL12 immunostaining in human normal epithelia. (B) Positive expression of CXCL12 in oral squamous cell carcinoma samples. CXCL12, C-X-C motif chemokine ligand 12.](ol-18-02-1099-g01){#f2-ol-0-0-10415}

![Survival analyses of 45 patients with OSCC. Kaplan-Meier plots with subsequent log-rank test results for (A) density of CD8^+^ TILs, (B) density of FoxP3^+^ TILs, (C) ratio of CD8^+^/FoxP3^+^ TILs and (D) CXCL12 expression in tumor cells. CXCL12, C-X-C motif chemokine ligand 12; FoxP3, forkhead box P3; OSCC, oral squamous cell carcinoma; TIL, tumor-infiltrating lymphocyte.](ol-18-02-1099-g02){#f3-ol-0-0-10415}

![Correlation between CXCL12% area and two TIL subpopulations. (A) Correlation of CXCL12% area with FoxP3^+^ TILs was indicated to be statistically significant (R^2^=0.481, P\<0.001). (B) No statistically significant correlation of CXCL12% area with CD8^+^ TILs was observed (R^2^=0.070, P=0.078). The linear regression line is plotted in each case. CXCL12, C-X-C motif chemokine ligand 12; FoxP3, forkhead box P3; TIL, tumor-infiltrating lymphocyte.](ol-18-02-1099-g03){#f4-ol-0-0-10415}

![CXCL12 may influence the distribution of FoxP3^+^ TILs. (A) High CXCL12 expression region. (B) Large number of FoxP3^+^ TILs infiltrating stroma. (A and B) Stroma cells with high CXCL12 expression (blue circle) were surrounded by numerous FoxP3^+^ TILs (black arrows). (C) Low CXCL12 expression region. (D) Small number of FoxP3^+^ TILs infiltrating stroma. CXCL12, C-X-C motif chemokine ligand 12; FoxP3, forkhead box P3; TIL, tumor-infiltrating lymphocyte.](ol-18-02-1099-g04){#f5-ol-0-0-10415}

###### 

Expressions levels of FoxP3 and CD8 in TILs in oral squamous cell carcinoma.

  Variables                            FoxP3^+^ TIL   CD8^+^ TIL
  ------------------------------------ -------------- ------------
  Number of patients, n                45 (100%)      45 (100%)
  Average number per 0.0625 mm^2^, n   50.4           111.9
  Range                                9--99          7--259
  Location                             Stroma         Stroma

FoxP3, forkhead box P3; TIL, tumor-infiltrating lymphocyte.

###### 

Associations between clinicopathological parameters of patients with oral squamous cell carcinoma and densities of TILs.

                               FoxP3^+^ TIL   CD8^+^ TIL   CD8/FoxP3 ratio                                                                   
  ----------------------- ---- -------------- ------------ ----------------------------------------------------- ---- ---- ------- ---- ---- -----------------------------------------------------
  Age                                                      0.174                                                           0.214             0.140
    ≤59                   24   12             12                                                                 11   13           10   14   
    \>59                  21   8              13                                                                 11   10           12   9    
  Sex                                                      0.231                                                           0.232             0.178
    Male                  24   11             13                                                                 12   12           13   11   
    Female                21   9              12                                                                 10   11           9    12   
  Tumor size                                               0.165                                                           0.233             0.142
    T1, T2                19   7              12                                                                 9    10           11   8    
    T3, T4                26   13             13                                                                 13   13           11   15   
  Lymph node metastasis                                    0.230                                                           0.142             
    Positive              19   8              11                                                                 11   8            12   7    0.065
    Negative              26   12             14                                                                 11   15           10   16   
  Stage (14)                                               0.125                                                           0.132             0.015^[a](#tfn3-ol-0-0-10415){ref-type="table-fn"}^
    I, II                 16   9              7                                                                  6    10           4    12   
    III, IV               29   11             18                                                                 16   13           18   11   
  Differentiation                                          0.095                                                           0.251             0.034^[a](#tfn3-ol-0-0-10415){ref-type="table-fn"}^
    Well-moderate         31   16             15                                                                 15   16           12   19   
    Poor                  14   4              10                                                                 7    7            10   4    
  Recurrence                                               0.022^[a](#tfn3-ol-0-0-10415){ref-type="table-fn"}^             0.097             0.002^[a](#tfn3-ol-0-0-10415){ref-type="table-fn"}^
    Yes                   24   7              17                                                                 14   10           17   7    
    No                    21   13             8                                                                  8    13           5    16   

FoxP3, forkhead box P3; TIL, tumor-infiltrating lymphocyte. P\<0.05 used to indicate statistical significance.

The difference is significant.

###### 

Associations between CXCL12 expression and clinicopathological parameters of patients with oral squamous cell carcinoma and density of TILs.

                               CXCL12 in tumor cells        
  ----------------------- ---- ----------------------- ---- -------------------------------------------------------
  Age                                                       0.056
    ≤59                   24   13                      11   
    \>59                  21   6                       15   
  Sex                                                       0.189
    Male                  24   9                       15   
    Female                21   10                      11   
  Tumor size                                                0.200
    T1, T2                19   7                       12   
    T3, T4                26   12                      14   
  Lymph node metastasis                                     0.200
    Positive              19   7                       12   
    Negative              26   12                      14   
  Stage (14)                                                \<0.001^[a](#tfn5-ol-0-0-10415){ref-type="table-fn"}^
    I, II                 16   12                      4    
    III, IV               29   7                       22   
  Differentiation                                           0.045^[a](#tfn5-ol-0-0-10415){ref-type="table-fn"}^
    Well-moderate         31   16                      15   
    Poor                  14   3                       11   
  Recurrence                                                0.011^[a](#tfn5-ol-0-0-10415){ref-type="table-fn"}^
    Yes                   24   6                       18   
    No                    21   13                      8    
  FoxP3^+^ TIL                                              \<0.001^[a](#tfn5-ol-0-0-10415){ref-type="table-fn"}^
    Low                   20   15                      5    
    High                  25   4                       21   
  CD8^+^ TIL                                                0.095
    Low                   22   7                       15   
    High                  23   12                      11   
  CD8/FoxP3 ratio                                           \<0.001^[a](#tfn5-ol-0-0-10415){ref-type="table-fn"}^
    Low                   22   2                       20   
    High                  23   17                      6    

CXCL12, C-X-C motif chemokine ligand 12; FoxP3, forkhead box P3; TIL, tumor-infiltrating lymphocyte. P\<0.05 used to indicate statistical significance.

The difference is significant.
